Safety Assessment of Povidone K-12 in IV Acetaminophen in Pediatrics

Area of Science:

• Pediatric pharmacology
• Drug excipient safety
• Renal function in neonates

Background:

• Excipient toxicity is a significant concern in pediatric medicine, especially for neonates.
• Povidone K-12, used in a new IV acetaminophen formulation, lacks safety data for neonates and infants with immature renal function.
• Povidone is renally eliminated and may accumulate in pediatric populations with impaired kidney function.

Purpose of the Study:

• To evaluate the safety of povidone K-12 as an excipient in intravenous formulations for pediatric use.
• To assess the potential for povidone K-12 accumulation in neonates, infants, and anuric patients.

Main Methods:

• Literature review of povidone K-12 safety data and case reports of accumulation.
• Molecular weight determination of povidone K-12 using size exclusion chromatography.
• Estimation of povidone K-12 proportions below the glomerular filtration threshold (25,000 g/mol).

Main Results:

• Case reports indicate povidone accumulation can lead to organ failure and death in adults.
• Previous data were insufficient to assess accumulation risk due to lack of reliable molecular weight information.
• Chromatographic analysis revealed less than 2 ppm of povidone K-12 exceeded the 25,000 g/mol threshold, indicating a low accumulation risk.

Conclusions:

• Povidone K-12 demonstrates a low risk of accumulation in pediatric patients with immature renal function.
• The excipient is unlikely to accumulate in neonates and infants, except possibly in anuric patients.
• Findings support the potential safety of povidone K-12 in pediatric IV formulations.